1. Signaling Pathways
  2. Anti-infection
  3. HIV

HIV

Human immunodeficiency virus

HIV (Human immunodeficiency virus) is a lentivirus (a subgroup of retrovirus) that causes the acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells. HIV infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. HIV infection leads to low levels of CD4+ T cells through a number of mechanisms, including apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10353S
    Raltegravir-d4
    Inhibitor
    Raltegravir-d4 is deuterium labeled Raltegravir. Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection.
    Raltegravir-d<sub>4</sub>
  • HY-P11157
    DrkBiT
    DrkBiT is a membrane-impermeable peptide competing with HiBiT. DrkBiT binds to LgBiT. DrkBiT can be used in the research of HIV-1 infection.
    DrkBiT
  • HY-W009783A
    Deoxymannojirimycin hydrochloride
    Inhibitor
    Deoxymannojirimycin hydrochloride is a selective class I α1,2-mannosidase inhibitor with an IC50 of 20 μM. Deoxymannojirimycin hydrochloride is also a N-linked glycosylation inhibitor. Deoxymannojirimycin hydrochloride has antiviral activity against HIV‐1 strains . Deoxymannojirimycin hydrochloride increases high mannose structures. Deoxymannojirimycin hydrochloride can be used for the study of liver cancer and colon cancer.
    Deoxymannojirimycin hydrochloride
  • HY-159150
    HIV-1 inhibitor-71
    Inhibitor
    HIV-1 inhibitor-71 (compound 2a) blocks the transport of endocytosed HIV-1 particles into nuclear envelope invagination (NEIs) that can inhibit productive infection.
    HIV-1 inhibitor-71
  • HY-152132
    CCR5 antagonist 3
    Inhibitor
    CCR5 antagonist 3 (Compound 26) is a CCR5 antagonist with an IC50 of 15.90 nM. CCR5 antagonist 3 shows broad-spectrum anti-HIV-1 activities.
    CCR5 antagonist 3
  • HY-150697
    HIV-1 inhibitor-44
    Inhibitor
    HIV-1 inhibitor-44 (compound 11l) is a HIV-1 reverse transcriptase inhibitor. HIV-1 inhibitor-44 shows inhibitory activity against wild-type HIV-1 strain with an EC50 value of 0.209 μM.
    HIV-1 inhibitor-44
  • HY-138562
    HIV-1 Nef-IN-1
    Inhibitor 98.60%
    HIV-1 Nef-IN-1 is an HIV-1 Nef protein inhibitor that efficiently competes for Nef-SH3Hck interactions with a Kd of 6.7 μM.
    HIV-1 Nef-IN-1
  • HY-N0492AR
    α-Lipoic Acid sodium (Standard)
    Inhibitor
    α-Lipoic Acid (sodium) (Standard) is the analytical standard of α-Lipoic Acid (sodium). This product is intended for research and analytical applications. α-Lipoic Acid (Thioctic acid) sodium is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid sodium inhibits NF-κB-dependent HIV-1 LTR activation. α-Lipoic Acid sodium induces endoplasmic reticulum (ER) stress-mediated apoptosis in hepatoma cells. α-Lipoic Acid sodium can be used with CPUL1 (HY-151802) to construct the self-assembled nanoaggregate CPUL1-LA NA, which has improved antitumor efficacy than CPUL1.
    α-Lipoic Acid sodium (Standard)
  • HY-132572
    HIV-1 integrase inhibitor 9
    Inhibitor
    HIV-1 integrase inhibitor 9 (compound 8a) is a potent HIV-1 RNase H inhibitor with an IC50 of 12.3 μM. HIV-1 integrase inhibitor 9 shows an antiviral activity.
    HIV-1 integrase inhibitor 9
  • HY-105394
    BEA 005
    Inhibitor
    BEA 005 is an antivirus agent. BEA 005 can block early systemic and mucosal infections with SIV and HIV-2.
    BEA 005
  • HY-N14366
    Fleephilone
    Inhibitor
    Fleephilone is a fungal metabolite that can be isolated from Trichoderma harzianum. Fleephilone is a HIV REV/RRE binding inhibitor. Fleephilone inhibits the binding of REV-protein to RRE RNA with an IC50 of 7.6 μM.
    Fleephilone
  • HY-147553
    HIV-1 inhibitor-36
    Inhibitor
    HIV-1 inhibitor-36 (Compound 2) is a potent HIV-1. HIV-1 inhibitor-36 has the potential for further development as novel latency reversing agents.
    HIV-1 inhibitor-36
  • HY-170483
    Antitumor agent-191
    Inhibitor
    Antitumor agent-191 (Compound 7) exhibits antiviral activity against HSV-1 and HIV with EC50 of 0.03 μM and 0.81 μM. Antitumor agent-191 exhibits potential antitumor efficacy, that inhibits cancer cell HepG2, WI-38, Vero and MCF-7, with IC50s of 19.6, 39.3, 18.3 and 28 μM, respectively.
    Antitumor agent-191
  • HY-10585S4
    Valproic acid-d4-1
    Inhibitor
    Valproic acid-d4-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
    Valproic acid-d<sub>4</sub>-1
  • HY-121611
    HI-236
    Inhibitor
    HI-236 is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase.? HI-236 inhibits HIV activity (wild type HTLVIIB IC50p24 < 0.001 μM).
    HI-236
  • HY-N11430
    F1839-I
    Inhibitor
    F1839-I is a compound that can be isolated from Stachybotrys. F1839-I has weak cytotoxicity and anti-HIV activity with an IC50 value of 15.6 μM.
    F1839-I
  • HY-13004R
    Maraviroc (Standard)
    Inhibitor
    Maraviroc (Standard) is the analytical standard of Maraviroc. This product is intended for research and analytical applications. Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV.
    Maraviroc (Standard)
  • HY-P10437
    VIRIP
    Inhibitor
    VIRIP (human α1-AT(353-372)) is a HIV-1 inhibitor. VIRIP blocks the entry of HIV-1 by interacting with gp41 fusion peptide. VIRIP can be used for virus research.
    VIRIP
  • HY-P11152
    HIV-1 tat Protein (1-9)
    Inhibitor
    HIV-1 tat Protein (1-9) occurs extracellularly and has a role in the immunosuppression of non-HIV-1-infected T cells in acquired AIDS. HIV-1 tat Protein (1-9) is an inhibitor of DP IV. HIV-1 tat Protein (1-9) can be synthesized by phase peptide synthesis with Fmoc (N-(9-fluorenyl)methoxycarbonyl) technique using the peptide synthesizer 431A. HIV-1 tat Protein (1-9) can be studied in research on HIV-1.
    HIV-1 tat Protein (1-9)
  • HY-113818
    Kadsuracoccinic acid A
    Inhibitor
    Kadsuracoccinic acid A is a tetracyclic natural compound that can be isolated from the stems of Kadsura coccinea. Kadsuracoccinic acid A has vitro anti-HIV-1 activitiy with an EC50 value of 68.7 μM.
    Kadsuracoccinic acid A
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.